英国胰腺癌高风险人群的风险分层监测:EUROPAC研究结果
BACKGROUND: Surveillance of individuals with a familial predisposition to pancreatic ductal adenocarcinoma (PDAC) is likely to increase overall survival. Our objective was to determine the impact of EUROPAC risk-stratification (Family Risk, FR), in such predisposed individuals.…
要点
- 无论致病性变异状态如何,风险分层均有助于发现胰腺肿瘤性病变。
核心结论
- 风险分层监测可在有无致病性变异的个体中识别胰腺肿瘤性病变,提示该方法的关键价值。
研究设计与样本
- 观察性研究纳入2000年1月至2025年4月注册的无症状胰腺癌监测个体893人,中位年龄52岁。
- 比较2020年前20年未分层监测的508人(404例PV-,104例PV+)与2020年后5年应用家族风险分层的385人(269例PV-,116例PV+)。
主要发现
- PV-个体中显著发现者后续检出突变,许多不在英国基因检测目录中,其家族风险>30。
- 病变检出前监测中位时间(IQR)为4(2-7)年;EUROPAC检出的前驱病变或胰腺癌中78%为II期或更低。
临床怎么用
- 对胰腺癌高风险个体应实施家族风险分层监测,以提高可手术病变检出率。
- PV-个体若家族风险>30且发现显著胰腺病变,应考虑额外胚系检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surveillance of individuals with a familial predisposition to pancreatic ductal adenocarcinoma (PDAC) is likely to increase overall survival. Our objective was to determine the impact of EUROPAC risk-stratification (Family Risk, FR), in such predisposed individuals. METHODS: Observational study of registered asymptomatic individuals undergoing surveillance for PDAC. Individuals without a known pathogenic variant (PV-), ineligible for genetic assessment in the NHS, in whom significant pancreatic lesions were found, were subjected to additional germline testing. RESULTS: Between January 2000 and April 2025, 893 individuals started surveillance, median age of 52 years. 508 individuals (404 PV- and 104 with a pathogenic variant (PV+)) in the 20 years prior to 2020 without stratification were compared to 385 (269 PV- and 116 PV+) in the five years from 2020 who had FR risk-stratification applied. Four (0·8 %) individuals had actionable pancreatic findings prior to risk stratification vs. 14 (3·6 %), who underwent risk-stratified surveillance (p = 0·001). Pancreatic lesions deemed operable were found in three (0·6 %) and 11 (3 %), p = 0·007, with two (0·4 %) and nine (2 %) undergoing resection, p = 0·009, respectively. PV- individuals with significant findings were subsequently found to contain mutations, many not in the UK genetics test directory, provided the FR was > 30. The median (IQR) time in surveillance prior to a lesion being detected was four (2 - 7) years. Overall, 78 % of EUROPAC detected precursor lesions or pancreatic cancers were stage II or lower. CONCLUSION: The risk-stratified group (FR) identifies neoplastic pancreatic lesion in individuals, regardless of PV status suggesting the key usefulness of this approach.
引用
- Hopley PJ, Peysner R, Boughey A, et al. Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC). Eur J Cancer. 2026. PMID: 41740463. doi:10.1016/j.ejca.2026.116592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。